Luis Alfonso Zarco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luis Alfonso Zarco has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Alejandra Taborda
Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
1 shared publicationAlex Rovira Cañellas
Radiologist and Neuroradiologist Head of the Neuroradiology Department, Hospital Universitario Vall d'Hebron, Centro de Esclerosis Múltiple de Cataluña (CEMCAT), Barcelona, Spain; Professor, Universidad Autónoma de Barcelona
1 shared publicationAndrés Felipe Cárdenas-Cruz
Neurology Resident, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia
1 shared publication- Andrés Felipe Cárdenas-Cruz
Neurology Resident, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia
1 shared publication - Camilo Alberto González González
Departamento de Medicina Interna, Unidad de Nefrología Hospital Universitario San Ignacio Bogotá Colombia
1 shared publication - Carlos Alvarado-De la Hoz
Department of Neurology, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia
1 shared publication
Latest Publications
- Open Access
- 25 October 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106804
Paramagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: A systematic review of the literature
- 25 October 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106804
Open AccessParamagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: A systematic review of the literature
- Open Access
- 2 September 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106721
Headache in optic neuritis: A retrospective case-control study revealing clinical and radiological associations of an underrecognized symptom
- 2 September 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106721
Open AccessHeadache in optic neuritis: A retrospective case-control study revealing clinical and radiological associations of an underrecognized symptom
- 7 April 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (6) , 1274-1280
Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders
Background: Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option. This study describes improvement and safety outcomes with TPE.Methods: We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. The primary outcome was an improvement in the visual acuity scale (VOS). We described the data and used multivariate logistic regression to identify factors associated with response.Results: Eighty‐three patients received 558 TPE sessions. Mean age was 40.9 years (±13.7 years); 73.5% were women, 50.1% were first attack, and 10.7% were bilateral. Median VOS: 5 (range [R], 2–7). Median time between onset and TPE was 8 days (R, 1–32). By Keegan's criteria, 82.4% experience improvement and 78.3% improve in at least 1 point in VOS. Age and pre‐TPE VOS were related to improvement. Low fibrinogen occurs in 26% sessions.Conclusion: TPE is effective and safety for ON in NMOSD patients. There is a need for a clinical trial using a therapeutic equivalent.
- 7 April 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (6) , 1274-1280
Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders
Background: Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option. This study describes improvement and safety outcomes with TPE.Methods: We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. The primary outcome was an improvement in the visual acuity scale (VOS). We described the data and used multivariate logistic regression to identify factors associated with response.Results: Eighty‐three patients received 558 TPE sessions. Mean age was 40.9 years (±13.7 years); 73.5% were women, 50.1% were first attack, and 10.7% were bilateral. Median VOS: 5 (range [R], 2–7). Median time between onset and TPE was 8 days (R, 1–32). By Keegan's criteria, 82.4% experience improvement and 78.3% improve in at least 1 point in VOS. Age and pre‐TPE VOS were related to improvement. Low fibrinogen occurs in 26% sessions.Conclusion: TPE is effective and safety for ON in NMOSD patients. There is a need for a clinical trial using a therapeutic equivalent.
- Open Access
- 1 August 2013
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 34 (1) , 110-7
Costo-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia
Costo-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia
- 1 August 2013
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 34 (1) , 110-7
Open AccessCosto-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia
Costo-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia